Heart Attack News and Research

RSS

COVID-19 increases heart attack rates in people with atherosclerotic cardiovascular disease

Individuals with genetic high cholesterol, heart disease or both, who were infected with COVID-19 had more heart attacks according to new research by the FH Foundation.

28 May 2021

Little evidence for mRNA COVID-19 vaccine-associated thrombocytopenia, suggests new FDA study

Even as a host of vaccines have been rolled out to counter the coronavirus disease 2019 (COVID-19) pandemic, some serious adverse effects have been reported, in the form of thrombocytopenia. A new study in the journal Vaccine reports the results of an evaluation of reported cases of this condition, using data from the Vaccine Adverse Event Reporting System (VAERS).

24 May 2021

Landmark study confirms that controlled blood pressure is key to prevent stroke, heart disease

Follow-up data from the landmark SPRINT study of the effect of high blood pressure on cardiovascular disease have confirmed that aggressive blood pressure management -- lowering systolic blood pressure to less than 120 mm Hg -- dramatically reduces the risk of heart disease, stroke, and death from these diseases, as well as death from all causes, compared to lowering systolic blood pressure to less than 140 mm Hg.

22 May 2021

Young Latinx adults who experience heart-focused anxiety face greater risk for mental health disorders

For coffee drinkers, a common scenario might involve drinking an extra cup only to end up with a racing heart and a subtle reminder to themselves to cut down the caffeine.

21 May 2021

A study reports the first case of an upper extremity deep vein thrombosis (DVT) recurrence due to COVID-19 infection

Researchers have reported the first case of COVID-19 triggering a rare occurrence of potentially severe blood clots forming in the arms.

19 May 2021

Randomized clinical trials compare effects of coronary revascularization versus medical therapy alone

A rigorous meta-analysis of randomized clinical trials (RCTs) that compared the effects of medical therapies alone with medical therapies plus revascularization in patients with stable ischemic heart disease (SIHD) was presented at EuroPCR on May 18, 2021.

19 May 2021

New approach could allow cardiologists to predict future heart attacks in high-risk patients

Analysing the forces at work behind the obstructions that cause heart attacks is crucial for identifying patients at risk of these events, says a study published today in eLife.

19 May 2021

COVID-19 pandemic causes disproportionate rise in cardiovascular deaths among racial, ethnic minorities

In the early months of the COVID-19 pandemic, the United States experienced higher rates of heart disease and cerebrovascular disease deaths, relative to the corresponding months the previous year.

18 May 2021

Sotagliflozin reduces adverse cardiovascular events across patients with diabetes, heart failure

Patients with both diabetes and heart failure who were treated with sotagliflozin, a novel investigational drug for diabetes, for a median of nine to 16 months experienced reductions of 22% to 43% in the risk of death or worsening heart failure compared with similar patients who were treated with a placebo

18 May 2021

Study raises more concerns about the use of combined EPA/DHA through supplements

Doctors often recommend Omega-3s to help patients lower their cholesterol and improve heart health. Those Omega-3s can come from fatty fish like salmon and mackerel, or supplements that often contain a combination of the acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA).

17 May 2021

Rivaroxaban reduces the occurrence of severe ischemic events in patients with peripheral artery disease

Rivaroxaban, in addition to low-dose aspirin, significantly reduced the occurrence of total severe events of the heart, limb or brain and issues related to other vascular complications in patients with symptomatic peripheral artery disease (PAD) who underwent lower extremity revascularization, a procedure to open blocked arteries in the leg.

17 May 2021

Frequent blood testing protocol for heart attack did not improve patient outcomes after one year

Using more sensitive and frequent repeat testing of a blood test that indicates heart injury to guide the treatment of low-risk patients with symptoms of a possible heart attack resulted in patients being discharged earlier and receiving fewer cardiac stress tests but did not improve patient outcomes after one year, according to research presented at the American College of Cardiology's 70th Annual Scientific Session.

17 May 2021

STEMI patients with multi-vessel disease have no benefit from FFR-guided PCI

In patients who had a coronary stent inserted after experiencing the most severe type of heart attack, the use of a technique that measures blood flow and pressure through a partially blocked artery to determine if a second stenting procedure is needed did not improve outcomes and was more costly than using angiography, or a heart X-ray, alone to guide the procedure, according to research presented at the American College of Cardiology’s 70th Annual Scientific Session.

17 May 2021

Brief pulses of ultrasound delivered to nerves in renal arteries reduce drug-resistant blood pressure

Brief pulses of ultrasound delivered to nerves near the kidney produced a clinically meaningful drop in blood pressure in people whose hypertension did not respond to a triple cocktail of medications, reports a new study led by researchers at Columbia University Vagelos College of Physicians and Surgeons and NewYork-Presbyterian.

17 May 2021

Sacubitril/valsartan drug did not significantly reduce cardiovascular death after heart attack

The heart failure drug sacubitril/valsartan did not significantly reduce the rate of heart failure or cardiovascular death following a heart attack compared to ramipril, an angiotensin-converting enzyme (ACE) inhibitor proven effective in improving survival following heart attacks.

17 May 2021

Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes

Approval is the most significant advancement in the treatment of chronic kidney disease in more than 20 years. In DAPA-CKD Phase III trial, Farxiga demonstrated unprecedented reduction in the risk of the composite of worsening of renal function, end-stage kidney disease and cardiovascular or renal death.

From AstraZeneca 14 May 2021

Manganese‐enhanced MRI provides more accurate details of heart function after a heart attack

According to the British Heart Foundation, heart and circulatory diseases cause more than a quarter (27 per cent) of all deaths in the UK, which equates to more than 160,000 deaths each year - or one death every three minutes.

11 May 2021

Blocking fat-busting enzyme with a drug compromises cardiac repair during acute heart failure

Blocking the fat-busting enzyme lipoxygenase with a synthetic inhibitor throws the immune system's innate inflammatory response out of whack, compromising cardiac repair during acute heart failure, USF Health researchers found.

10 May 2021

Moderate alcohol intake may be heart protective by reducing stress-related brain signals

Moderate alcohol intake--defined as no more than one alcoholic drink for women and two for men per day--has been associated with a lower risk of dying from cardiovascular disease when compared with individuals who abstain from drinking or partake in excessive drinking, according to a new study being presented at the American College of Cardiology's 70th Annual Scientific Session.

6 May 2021

Study reveals sex differences in evaluation and treatment of young adults with chest pain

Among younger adults visiting the emergency department for chest pain, women may be getting the short end of the stick.

6 May 2021

Heart Attack News and Research

COVID-19 increases heart attack rates in people with atherosclerotic cardiovascular disease

Little evidence for mRNA COVID-19 vaccine-associated thrombocytopenia, suggests new FDA study

Landmark study confirms that controlled blood pressure is key to prevent stroke, heart disease

Young Latinx adults who experience heart-focused anxiety face greater risk for mental health disorders

A study reports the first case of an upper extremity deep vein thrombosis (DVT) recurrence due to COVID-19 infection

Randomized clinical trials compare effects of coronary revascularization versus medical therapy alone

New approach could allow cardiologists to predict future heart attacks in high-risk patients

COVID-19 pandemic causes disproportionate rise in cardiovascular deaths among racial, ethnic minorities

Sotagliflozin reduces adverse cardiovascular events across patients with diabetes, heart failure

Study raises more concerns about the use of combined EPA/DHA through supplements

Rivaroxaban reduces the occurrence of severe ischemic events in patients with peripheral artery disease

Frequent blood testing protocol for heart attack did not improve patient outcomes after one year

STEMI patients with multi-vessel disease have no benefit from FFR-guided PCI

Brief pulses of ultrasound delivered to nerves in renal arteries reduce drug-resistant blood pressure

Sacubitril/valsartan drug did not significantly reduce cardiovascular death after heart attack

Farxiga approved in the US for the treatment of chronic kidney disease in patients at risk of progression with and without type-2 diabetes

Manganese‐enhanced MRI provides more accurate details of heart function after a heart attack

Blocking fat-busting enzyme with a drug compromises cardiac repair during acute heart failure

Moderate alcohol intake may be heart protective by reducing stress-related brain signals

Study reveals sex differences in evaluation and treatment of young adults with chest pain

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News